ASP Isotopes Inc. (ASPI)

ASP Isotopes is moving from facility construction toward early commercialization across helium, stable isotopes, radiopharmacy, and nuclear fuels. Recent updates include stable liquid-helium production, a South African joint venture for HALEU (high-assay low-enriched uranium), and a long-term target exceeding $300 million in EBITDA by 2031. EBITDA means earnings before interest, taxes, depreciation, and amortization, and serves as a measure of operating profitability. ASPI was down 3.47% in the current regular session on November 2, 2026.